Biotech · Private company
Alkermes, Inc.
Track this companyFree. Adds Alkermes, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2512 recruiting or active
Pipeline programs22From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline22
- ALKS 2680 Dose 1Phase 3 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680 Dose 1Phase 3 · Narcolepsy Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680 Dose 2Phase 3 · Narcolepsy Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680 Dose 2Phase 3 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680 Dose 3Phase 3 · Narcolepsy Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680, 10mgPhase 3 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680, 14mgPhase 3 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680, 18mgPhase 3 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680, 4mgPhase 3 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680, 6mgPhase 3 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680, 8mgPhase 3 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 3831Phase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- OlanzapinePhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- OLZ/SAMPhase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- OLZ/SAMPhase 3 · Bipolar I DisorderClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680Phase 2 · Narcolepsy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680Phase 2 · Idiopathic HypersomniaClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 2680Phase 2 · Narcolepsy Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 7290Phase 2 · Attention Deficit Disorder With Hyperactivity (ADHD)ClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 7290 DosePhase 2 · Major Depressive Disorder (MDD)ClinicalTrials.gov · fetched Nov 12, 2026
- LYBALVIPhase 1 · Focus of Study is on Healthy Lactating WomenClinicalTrials.gov · fetched Nov 12, 2026
- OLZ/SAMBipolar 1 DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive DisorderPHASE2 · RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07901179 · fetched Nov 12, 2026
- Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy ControlsNA · RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07680114 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)PHASE3 · RECRUITING · started Aug 13, 2026ClinicalTrials.gov NCT07540897 · fetched Nov 12, 2026
- A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)PHASE2 · RECRUITING · started Aug 10, 2026ClinicalTrials.gov NCT07755410 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2PHASE3 · RECRUITING · started Apr 22, 2026ClinicalTrials.gov NCT07502443 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1PHASE3 · RECRUITING · started Apr 6, 2026ClinicalTrials.gov NCT07455383 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaPHASE2 · ACTIVE_NOT_RECRUITING · started May 22, 2025ClinicalTrials.gov NCT06843590 · fetched Nov 12, 2026
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPHASE2_PHASE3 · RECRUITING · started Jan 27, 2025ClinicalTrials.gov NCT06767683 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2PHASE2 · COMPLETED · started Jul 26, 2024ClinicalTrials.gov NCT06555783 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)PHASE2 · COMPLETED · started Mar 24, 2024ClinicalTrials.gov NCT06358950 · fetched Nov 12, 2026
- C-Cog in Early Course Schizophrenia StudyPHASE4 · TERMINATED · started Jan 23, 2024ClinicalTrials.gov NCT05662306 · fetched Nov 12, 2026
- Neuroplasticity in Maternal Opioid Use Disorder (OUD)NA · SUSPENDED · started Jan 1, 2023ClinicalTrials.gov NCT05495984 · fetched Nov 12, 2026
- Study of the Breast Milk Pharmacokinetics of Olanzapine and SamidorphanPHASE1 · COMPLETED · started Sep 14, 2022ClinicalTrials.gov NCT05547100 · fetched Nov 12, 2026
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPHASE3 · RECRUITING · started Jun 30, 2022ClinicalTrials.gov NCT05303064 · fetched Nov 12, 2026
- Effects of Ketamine on ERP/EEG Measures in Healthy VolunteersEARLY_PHASE1 · COMPLETED · started May 26, 2022ClinicalTrials.gov NCT04928703 · fetched Nov 12, 2026
- Naltrexone in AUD Reward DrinkersPHASE4 · RECRUITING · started Mar 7, 2022ClinicalTrials.gov NCT05028062 · fetched Nov 12, 2026
- Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsPHASE3 · ENROLLING_BY_INVITATION · started Oct 22, 2021ClinicalTrials.gov NCT04987229 · fetched Nov 12, 2026
- Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I DisorderPHASE1 · COMPLETED · started Jul 22, 2021ClinicalTrials.gov NCT04987658 · fetched Nov 12, 2026
- Repeated Cannabis Administration on Experimental Pain and Abuse LiabilityPHASE2 · COMPLETED · started Jun 1, 2021ClinicalTrials.gov NCT04576507 · fetched Nov 12, 2026
- Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia EpisodePHASE4 · TERMINATED · started Dec 16, 2019ClinicalTrials.gov NCT04203056 · fetched Nov 12, 2026
- Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)COMPLETED · started Mar 28, 2019ClinicalTrials.gov NCT03919994 · fetched Nov 12, 2026
- Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831PHASE3 · COMPLETED · started Jun 15, 2017ClinicalTrials.gov NCT03201757 · fetched Nov 12, 2026
- Harm Reduction With Pharmacotherapy (HaRP)PHASE2 · COMPLETED · started Aug 1, 2013ClinicalTrials.gov NCT01932801 · fetched Nov 12, 2026
- National Pregnancy Registry for Psychiatric MedicationsRECRUITING · started Nov 1, 2008ClinicalTrials.gov NCT01246765 · fetched Nov 12, 2026
- An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)AVAILABLEClinicalTrials.gov NCT07744113 · fetched Nov 12, 2026